Canada, Uganda test drug to treat brain disease

May 1, 2013 by Michel Comte

Canada is funding testing in Uganda of a popular off-patent antidepressant drug to fight a fungal brain disease that claims more than half a million lives in sub-Saharan Africa every year.

Sertraline, better known as Zoloft or Lustral, was first introduced by pharmaceutical giant in 1991. It has since become the second-most prescribed antidepressant in the United States.

But recent lab work at the University of Utah found that the drug also has a potent fungicidal effect, with several women taking it to alleviate symptoms of premenstrual syndrome reporting it also cleared up their .

With Canadian backing, researchers at Uganda's Infectious Disease Institute at Makerere University now hope to show that it can be used to stem early deaths from —an infection of the tissue covering the brain that claims 600,000 lives in sub-Saharan Africa annually.

"We're hoping to teach an old drug new tricks," lead researcher David Meya told AFP in a telephone interview from Uganda Tuesday.

"Our hope is that if this drug works against cryptococcal meningitis, we can cut by 40 to 50 percent, which would be a huge leap."

More than 30 percent of patients die within 10 weeks of onset of the disease, which has been linked to AIDS.

Currently, it is being treated with one of two drugs: flucytosine and . Both were developed in the 1950s and are "very expensive and not widely available in sub-Saharan Africa," Meya said.

A third drug, , has also been tried but is less effective, he added.

"So if we discover another drug that is more effective against cryptococcal meningitis and is cheaper, we can substantially bring down mortality rates in sub-Saharan Africa."

Developing and testing a new drug from scratch typically takes seven to 10 years. Repurposing a drug already on the market in this case is expected to take only four years, Meya said.

"We already know this drug's safety profile. We just need to do a clinical trial to see how effective varying amounts of the drug are at treating a new disease," he noted.

Furthermore, since drug patents for are now expired, it would be possible for generic drug makers to produce and sell it more cheaply.

The Canadian government is helping Meya's team with $100,000 (US$99,364) in seed funding through a program called Grand Challenges Canada.

It is one of more than 100 grants to innovators in 13 developing nations and in Canada "to pursue bold, creative ideas for tackling health problems," according to a statement.

The funds—$10.9 million in total—are to be spent on trying out remote diagnostics and monitoring, health protection, as well as drug and vaccine development and accessibility.

Other projects include a vaccine for smokers against nicotine's addictive effect; a glucose meter cell phone attachment for diabetics and a cheap instant test strip to diagnose deadly diseases like dengue and Ebola.

Explore further: Biologists prove ZOLOFT packs potential to fight fungal meningitis

Related Stories

Combo therapy helps knock out fungal meningitis

April 3, 2013

(HealthDay)— A drug regimen containing two powerful antifungal medicines—amphotericin B and flucytosine—reduced the risk of dying from cryptococcal meningitis by 40 percent compared to treatment with amphotericin B ...

Recommended for you

Re-framing the placebo effect and informed consent

October 29, 2015

(Medical Xpress)—Imagine that your doctor knows from evidence-based studies that if he tells you about certain, small side-effects to a particular drug, you are significantly more likely to experience that side effect than ...

Can exercise be replaced with a pill?

October 2, 2015

Everyone knows that exercise improves health, and ongoing research continues to uncover increasingly detailed information on its benefits for metabolism, circulation, and improved functioning of organs such as the heart, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.